Nexalin Technology (NXL) Q4 2024 earnings summary

Executive summary

• Focused on developing neurostimulation devices (Gen-2 and Gen-3) for mental health conditions, with Gen-2 approved in China and Gen-3 in FDA pre-submission in the US.

• Revenue primarily from legacy Gen-1 device support and sales of supplies; new device sales in the US paused pending regulatory clearance.

• Joint venture in China with Wider Come Limited for Gen-2 device commercialization; company holds 48% stake.

• Recent regulatory approvals in Brazil and Oman for Gen-2 device expand international footprint.

Financial highlights

• 2024 revenue: $168,721 (up 52% from $110,748 in 2023), mainly from supplies and parts.

• Gross profit: $132,128 (78% margin), up from $85,060 (77% margin) in 2023.

• Operating expenses: $7.89M (up 36%), driven by higher SG&A, professional fees, and stock compensation.

• Net loss: $7.61M (vs. $4.69M in 2023); accumulated deficit: $84.6M.

• Cash and equivalents: $574K; short-term investments: $2.91M as of Dec 31, 2024.

• Working capital: $3.41M as of year-end 2024.

Outlook and guidance

• Company expects continued operating losses and negative cash flows as it pursues regulatory approvals and commercialization.

• Management notes substantial doubt about ability to continue as a going concern without additional capital or successful execution of business plan.

• Focus remains on FDA clearance for Gen-3, expansion in China, and leveraging new approvals in Brazil and Oman.